1. Home
  2. NTLA vs SSTK Comparison

NTLA vs SSTK Comparison

Compare NTLA & SSTK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • NTLA
  • SSTK
  • Stock Information
  • Founded
  • NTLA 2014
  • SSTK 2003
  • Country
  • NTLA United States
  • SSTK United States
  • Employees
  • NTLA N/A
  • SSTK N/A
  • Industry
  • NTLA Biotechnology: In Vitro & In Vivo Diagnostic Substances
  • SSTK EDP Services
  • Sector
  • NTLA Health Care
  • SSTK Technology
  • Exchange
  • NTLA Nasdaq
  • SSTK Nasdaq
  • Market Cap
  • NTLA 1.4B
  • SSTK 1.2B
  • IPO Year
  • NTLA 2016
  • SSTK 2012
  • Fundamental
  • Price
  • NTLA $13.80
  • SSTK $30.03
  • Analyst Decision
  • NTLA Buy
  • SSTK Strong Buy
  • Analyst Count
  • NTLA 17
  • SSTK 3
  • Target Price
  • NTLA $56.63
  • SSTK $53.67
  • AVG Volume (30 Days)
  • NTLA 3.1M
  • SSTK 538.5K
  • Earning Date
  • NTLA 11-07-2024
  • SSTK 10-29-2024
  • Dividend Yield
  • NTLA N/A
  • SSTK 3.96%
  • EPS Growth
  • NTLA N/A
  • SSTK N/A
  • EPS
  • NTLA N/A
  • SSTK 1.01
  • Revenue
  • NTLA $43,086,000.00
  • SSTK $902,175,000.00
  • Revenue This Year
  • NTLA $50.73
  • SSTK $9.28
  • Revenue Next Year
  • NTLA $8.69
  • SSTK $12.47
  • P/E Ratio
  • NTLA N/A
  • SSTK $30.16
  • Revenue Growth
  • NTLA N/A
  • SSTK 3.09
  • 52 Week Low
  • NTLA $12.82
  • SSTK $28.85
  • 52 Week High
  • NTLA $34.87
  • SSTK $54.41
  • Technical
  • Relative Strength Index (RSI)
  • NTLA 36.15
  • SSTK 41.33
  • Support Level
  • NTLA $12.82
  • SSTK $28.85
  • Resistance Level
  • NTLA $17.30
  • SSTK $30.47
  • Average True Range (ATR)
  • NTLA 1.11
  • SSTK 1.03
  • MACD
  • NTLA -0.11
  • SSTK -0.24
  • Stochastic Oscillator
  • NTLA 19.56
  • SSTK 18.73

About NTLA Intellia Therapeutics Inc.

Intellia Therapeutics is a gene editing company focused on the development of Crispr/Cas9-based therapeutics. Crispr/Cas9 stands for Clustered Regularly Interspaced Short Palindromic Repeats (Crispr)/Crispr-associated protein 9 (Cas9), which is a revolutionary technology for precisely altering specific sequences of genomic DNA. Intellia is focused on using this technology to treat genetically defined diseases. It's evaluating multiple gene editing approaches using in vivo and ex vivo therapies to address diseases with high unmet medical needs, including ATTR amyloidosis, hereditary angioedema, sickle cell disease, and immuno-oncology. Intellia has formed collaborations with several companies to advance its pipeline, including narrow-moat Regeneron and wide-moat Novartis.

About SSTK Shutterstock Inc.

Shutterstock Inc is a U.S.-based company that is engaged in the provision of digital content. The content segment, whose offerings include licenses for Images, Footage, Music, 3 Dimensional, and Generative AI content. Data, Distribution, and Service offerings address customer demand for products and services that are beyond its Content licenses. The company generates the majority of its revenue from Content offerings. Geographically the company generates the majority of its revenue from the Domestic market.

Share on Social Networks: